The more business we did, the more we needed to know about the people we were considering working with. This was before the internet – so you couldn’t just go online and look someone up. The investigation companies only worked with big corporations and couldn’t help us. So I found the right resource and started LCF, to investigate legal, corporate and financial affairs.
RJ Valentine, Chairman The MBA GroupOctet Medical
Portfolio company profile
THE CONCEPT
Octet Medical is a medical technology company developing a first‑of‑its‑kind electrostatic therapeutic delivery platform designed to precisely administer drugs, biologics, and advanced wound care therapies. Its flagship technology, the OMEA® Delivery System, enables targeted, non‑invasive application using electrostatic microdroplet spray and electrospinning — improving therapeutic coverage, reducing waste, and enhancing patient outcomes. The platform is designed to be modular, portable, and compatible across multiple therapeutic payloads, positioning it as a scalable foundation for wound care, biologics, regenerative medicine, and beyond.
THE MISSION
Octet Medical’s mission is to revolutionize how therapies are delivered by providing clinicians with a convenient, handheld platform that enables precise, efficient, and patient‑friendly treatment — while supporting better clinical outcomes and streamlined workflows.
THE MBA GROUP DIFFERENCES
MBA Group partnered with Octet Medical early, providing strategic capital, governance support, and long‑term operational guidance. Beyond funding, MBA Group has helped Octet:
- Structure its platform strategy and IP roadmap
- Build an experienced board and advisory group
- Navigate complex regulatory and manufacturing considerations
- Position the company for strategic partnerships and institutional capital
THE RESULTS
Founded in 2018, Octet Medical has built a deep patent portfolio with over 100 issued and pending patents globally, completed multiple prototype generations, raised institutional capital, and advanced toward pilot manufacturing and clinical validation. The company is positioned for significant value creation through licensing, strategic partnerships, and potential acquisition within the advanced wound care and therapeutic delivery markets.